Publicidad
Caso clínico 10 de abril de 2018

Carcinoma de paratiroides: hallazgo en gammagrafía con 99mTc- Sestamibi

Referenciar Imprimir Descargar PDF

Referencias

  1. Kassahun W, Jonas S. Focus on parathyroid carcinoma. Int Jour Surg 2011; 9:13-19.
  2. Mohebati A, Shaha A, Shah J. Parathyroid carcinoma challenges in diagnosis and treatment. Hematol Oncol Clin N Am 2012; 26:1221-38.
  3. Alenezi S, Asaad S, Helgazzar A. Scintigraphic parathyroid imaging: concepts and new developments. Res Rep Nucl Med 2015; 5:9-18.
  4. Ruda J, Hollenbeak C, Stack B. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132:359-72.
  5. Cheon M, Choi J, Chung J, et al. Differential findings of Tc-99m SestaMIBI dual-phase parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism. Nucl Med Mol Imaging 2011; 45:276-84.
  6. Moralidis E. Radionuclide parathyroid imaging: a concise, updated review. Hell J Nucl Med 2013; 16:125-33.
  7. Kitapçi M, Tastekin G, Turgut M, et al. Preoperative localization of parathyroid carcinoma using Tc-99m MIBI. Clin Nucl Med 1993; 18:217-9.
  8. Singhal T, Jacobs M, Mantil J. Tc-99m Pertechnetate/Sestamibi subtraction scan in a case of parathyroid carcinoma. Clin Nucl Med 2008; 33:196-7.
  9. Campennì A, Ruggeri R, Sindoni A, et al. Parathyroid carcinoma as a challenging diagnosis: Report of three cases. Hormones 2012; 11:368-76.
  10. Arroyo O, Jiménez A, Lapeña L, et al. Gammagrafía con Tc-sestaMIBI en hiperparatiroidismo con diagnóstico histológico de carcinoma de paratiroides. Alasbimn Journal 2015; Abril.